# Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

> **NCT02111707** · PHASE4 · COMPLETED · sponsor: **University of Alberta** · enrollment: 534 (actual)

## Conditions studied

- Acute Pancreatitis

## Interventions

- **DRUG:** Rectal indomethacin 100mg one time before or after ERCP

## Key facts

- **NCT ID:** NCT02111707
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 534 (ACTUAL)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111707, "Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02111707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*